Medical Innovation Exchange

GSK hep B treatment’s efficacy slips 60% in full phase 2 readout, but phase 3 going ahead

https://www.fiercebiotech.com/biotech/gsk-sees-hep-b-treatments-efficacy-drop-60-full-phase-2-readout-still-plans-phase-3

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!